3Khand AU, Rankin AC, Kaye GC. Systematic review of the management of atrial fibrillation in patients with heart failure[J].Eur Heart J,2000,21 (8):614-632.
4Sarkozy A, Dorian P. Advances in the acute pharmacologic management of cardiac arrhythmias[J].Cur Cardiol Rep,2003,5(5):387-394.
5Christiansen EH ,Frost L,Andreasen F ,et al. Dose-related cardiac dectrophysiological effects of intravenous magnesium. A double-blind placebo-controlled dose-response study in patients with paroxysmal supraventricular tachycardia[J]. Europace,2000,2(4):320-326.
7Henyan N ,White CM. Adjunctive intravenous magnesium to reduce toxicity and enhance efficacy of class Ⅲ antiarrhythmic agents [J].Conn Med,2004,68(10):627-629.
5Gebker R, Jahnke C, Manka R, et al. Additional value of myocardial per- fusion imaging during dobutamine stress magnetic resonance for the as- sessment of coronary artery disease[J].Circ Cardiovasc Imaging,2008,1 (2) : 122-130.
7Duran R,Aladag N,Vatansever U,et al. The impact of Neonatal Re- suscitation Program courses on mortality and morbidity of newborn in- fants with perinatal asphyxia[J]. Brain Dev, 2008,30( 1 ) : 43-46.
10Christopher JA, Neil Satnam, Singh Michael. Aldosterone inhibition in patients with heart failure with preserved ejection fraction, the journal of the American Medical Association, 2013, 310(2):204.
